Our data suggest that targeting breast cancers with suboptimal doses of a CDK inhibitor may promote immune cell infiltration, upregulate PD-L1 in surviving cancer cells, and potentially be considered alongside checkpoint blockade. This evidence concerns the gene CD274 and breast carcinoma.